Thanks to the osteoblastic expression of receptors for GLP-1 in diabetes-related osteoporosis models, the continuous subcutaneous infusion of GLP-1 or Liraglutide normalized their impaired trabecular architecture and promoted bone formation [43]. The gene discussed is GLP1R; the disease is osteoporosis.